SCHEMBL4222642

SCHEMBL4222642

Cn1ncc2c(-c3ccc(NC(=O)Nc4ccccc4Cl)cc3)cncc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 5/20 0.53
POLB P06746 3/20 0.51
LCK P06239 4/20 0.49
HCK P08631 2/20 0.49
FLT3 P36888 4/20 0.48
CSF1R P07333 3/20 0.48
LYN P07948 3/20 0.48
KIT P10721 3/20 0.48
FLT1 P17948 3/20 0.48
FLT4 P35916 3/20 0.48
BLK P51451 3/20 0.48
ABL1 P00519 1/20 0.48
MAPT P10636 4/20 0.48
NPC1 O15118 4/20 0.48
RAB9A P51151 4/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4226770 0.92 KDR (0.54) KDRPOLBLCKHCKFLT3
SCHEMBL3846464 0.88 KDR (0.64) KDRLCKFLT3CSF1RLYN
SCHEMBL3844631 0.88 KDR (0.62) KDRLCKFLT3CSF1RLYN
SCHEMBL4229675 0.88 HTR2A (0.52) KDRPOLBLCKFLT3CSF1R
SCHEMBL3845211 0.87 KDR (0.58) KDRLCKFLT3CSF1RLYN
SCHEMBL4226760 0.87 KDR (0.56) KDRLCKFLT3CSF1RLYN
SCHEMBL13873268 0.85 SMN1; SMN2 (0.55) KDRMAPTNPC1RAB9AMEN1
SCHEMBL3847896 0.83 RIPK1 (0.55) KDRLCKFLT3CSF1RLYN
SCHEMBL4218145 0.83 KDR (0.69) KDRLCKFLT3CSF1RLYN
SCHEMBL13873222 0.80 RIPK1 (0.56) KDRLCKFLT3CSF1RLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125808-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME Bayer Schering Pharma Aktiengesellschaft (DE) 2009-12-02 EP claimed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US claimed
WO-2008071456-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO claimed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. BAYER SCHERING PHARMA AG (DE) 2009-03-05 US disclosed
WO-2008071456-A2 3-H-PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062273-A1 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same. KDR, FLT4, TIE1 KDR 1/4885POLB 3268/4885LCK 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.